10-Q: Humana Q1 2026 Earnings: Revenue Up, Net Income Down

Humana Inc. reported a 23.5% increase in total revenues for the first quarter of 2026, driven by strong membership growth in its Medicare business, though net income attributable to Humana decreased by 4.7%.

Summary

• Humana Inc. reported total revenues of $39.65 billion for the first quarter ended March 31, 2026, a 23.5% increase compared to $32.11 billion in the same period of 2025.
• Net income attributable to Humana was $1.19 billion, or $9.83 per diluted share, a decrease from $1.24 billion, or $10.30 per diluted share, in the first quarter of 2025.
• The company acquired MaxHealth, a primary care organization, for approximately $908 million in February 2026.
• Operating expenses increased by 25.9% to $37.89 billion, primarily due to a 27.0% rise in benefits expense.
• The benefit ratio increased to 89.4% from 87.0% in the prior year's quarter, while the operating cost ratio improved to 10.2% from 10.6%.
• Medicare Advantage membership saw significant growth, with Individual Medicare Advantage up 22.6% and Group Medicare Advantage up 27.3%.
• CenterWell segment revenues increased by 32.0% to $1.43 billion, but its income from operations decreased by 26.3%.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed-to-negative result, with strong revenue growth overshadowed by a decline in net income and an increasing benefit ratio, despite operational efficiencies in cost ratios.

Positives

• Total revenues increased by 23.5% to $39.65 billion, driven by strong membership growth in Medicare and higher per-member premiums.
• Premiums revenue saw a substantial increase of 23.6% to $37.71 billion, largely due to membership growth in Medicare Advantage and Part D plans.
• Services revenue grew by 25.7% to $1.68 billion, primarily from the expansion of the payor-agnostic client base in the CenterWell platform.
• Operating cost ratio improved to 10.2% from 10.6%, indicating increased administrative efficiency.
• Individual Medicare Advantage membership grew by 22.6%, and Medicare stand-alone PDP membership increased by 58.7%, demonstrating strong market penetration.
• The company maintained an investment-grade credit rating of BBB from S&P and Baa2 from Moody's.

Negatives

• Net income attributable to Humana decreased by 4.7% to $1.19 billion from $1.24 billion in the prior year's quarter.
• Benefits expense increased by 27.0% to $33.71 billion, outpacing revenue growth.
• The benefit ratio increased to 89.4% from 87.0%, indicating higher claims costs relative to premiums.
• CenterWell segment's income from operations decreased by 26.3% to $289 million, despite revenue growth.
• The operating cost ratio for the CenterWell segment increased to 94.5% from 91.1%.
• The company faces ongoing legal proceedings, including a securities litigation case and a lawsuit challenging the Medicare Advantage Star Ratings program.

Risks

• The Final RADV Rule, which eliminates the Fee-for-Service Adjuster, and any related regulatory, industry, or company reactions, could have a material adverse effect on results of operations, financial position, or cash flows.
• The ongoing lawsuit challenging the Medicare Advantage and Part D Star Ratings program, if not successful, could impact future performance.
• Changes in government healthcare programs, including Medicare and Medicaid, such as reductions in premium payments or increased member eligibility criteria without corresponding premium increases, may adversely affect results.
• The company is subject to various other lawsuits and regulatory matters that could result in substantial judgments, penalties, fines, or other sanctions.
• The company's investment portfolio is exposed to interest rate risk, and a 1% increase in interest rates could decrease the fair value of its securities by approximately $773 million.
• The company's ability to access capital and its borrowing costs could be impacted by adverse changes in its credit rating.

Future Outlook

The company's strategy is focused on offering affordable healthcare with a positive consumer experience in growing markets, leveraging an integrated care delivery model. Management believes this strategy positions them for long-term growth in membership and earnings. The company expects to incur additional charges over the course of its multi-year transformation program.

Management Comments

• "Our strategy is to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics."
• "We believe this strategy is positioning us for long-term growth in both membership and earnings."
• "We are committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members."

Industry Context

StockSavvy.ai notes that Humana's Q1 2026 results reflect ongoing trends in the U.S. healthcare industry, particularly the continued growth and importance of Medicare Advantage programs. The company's strategic focus on integrated care delivery and its acquisition of primary care assets like MaxHealth align with the industry's shift towards value-based care and a more holistic approach to member well-being. The increased competition and regulatory scrutiny, especially concerning Medicare Advantage payment models and star ratings, are significant factors impacting profitability and operational strategies across the sector.

Comparison to Industry Standards

• Humana's benefit ratio of 89.4% for Q1 2026 is higher than the industry average for health insurers, which typically aims for ratios in the mid-80s, suggesting higher medical cost trends or pricing pressures.
• The company's operating cost ratio of 10.2% is within the typical range for large health insurers, which often falls between 8-12%, indicating efficient administrative operations relative to revenue.
• The significant membership growth in Medicare Advantage (22.6% for Individual MA) outpaces the overall U.S. senior population growth, indicating successful market share gains against competitors like UnitedHealth Group, Elevance Health, and CVS Health (Aetna).
• The acquisition of MaxHealth for $908 million is a strategic move to bolster primary care capabilities, a trend seen across the industry as companies like Optum (UnitedHealth Group) expand their owned physician networks to improve care coordination and cost control.

Legal Proceedings

• Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the U.S. Department of Health and Human Services regarding the Final RADV Rule, which was vacated by a district court but is now under appeal.
• A putative stockholder class action lawsuit alleges false or misleading statements in SEC filings and statements to the financial markets regarding financial performance, medical costs, Star Ratings, and distribution relationships.
• Derivative actions allege breach of fiduciary duty by directors and officers related to the same claimed acts and omissions in the securities litigation.
• Humana filed suit against HHS and CMS challenging the administration of the Medicare Advantage and Part D Star Ratings program; a decision rejecting the challenge was issued, and an appeal is pending.
• The Department of Justice intervened in a qui tam lawsuit alleging civil violations related to non-commission payments to call center broker partners and marketing of Medicare Advantage plans.
• A class action lawsuit alleging violations of the Telephone Consumer Protection Act (TCPA) will proceed.
• The company is subject to ongoing reviews and investigations by various state and federal regulatory authorities concerning claims payment, statutory capital, contracting, risk adjustment, and other business practices.

Stakeholder Impact

• Shareholders: Decreased net income and EPS may impact investor sentiment, though revenue growth and strategic acquisitions could be viewed positively.
• Members: Continued focus on affordable healthcare and integrated care delivery aims to improve health outcomes and member experience. Changes in Medicare Advantage funding and Star Ratings could indirectly affect plan benefits or costs.
• Employees: The company's transformation program includes workforce optimization and severance charges, indicating potential impacts on employees.
• Providers: The shift towards value-based arrangements and integrated care delivery impacts how providers are compensated and managed.
• Creditors: The issuance of junior subordinated notes and existing debt levels are relevant to creditors, though the company maintains an investment-grade credit rating.

Next Steps

• Continue to execute on the integrated care delivery model to drive long-term growth in membership and earnings.
• Manage cost structure and operating model through the multi-year transformation program.
• Monitor and respond to regulatory changes, particularly concerning Medicare Advantage payment models and Star Ratings.
• Integrate the recently acquired MaxHealth business.
• Repay borrowings under the commercial paper program using proceeds from the junior subordinated notes issuance.

Key Dates

Recommendation

Humana demonstrates strong revenue growth and market share expansion in its core Medicare business, supported by strategic acquisitions. However, the decline in net income, increased benefit ratio, and ongoing legal and regulatory challenges, particularly concerning Medicare risk adjustment and Star Ratings, present significant headwinds. While the company is executing on cost efficiencies and strategic initiatives, the uncertainty surrounding regulatory outcomes and the increasing cost of benefits warrant a cautious 'hold' stance until these risks are better understood and mitigated.

Keywords

Humana, 10-Q, Quarterly Report, Healthcare, Health Insurance, Medicare Advantage, Medicaid, CenterWell, Financial Results, SEC Filing